Bellevue Group AG Sells 110,739 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Bellevue Group AG decreased its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 12.0% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 809,095 shares of the biopharmaceutical company’s stock after selling 110,739 shares during the quarter. Alnylam Pharmaceuticals comprises approximately 3.6% of Bellevue Group AG’s holdings, making the stock its 5th largest position. Bellevue Group AG owned approximately 0.63% of Alnylam Pharmaceuticals worth $222,525,000 at the end of the most recent quarter.

Several other large investors have also bought and sold shares of the company. TD Asset Management Inc lifted its holdings in Alnylam Pharmaceuticals by 6.0% in the 2nd quarter. TD Asset Management Inc now owns 489,940 shares of the biopharmaceutical company’s stock valued at $119,055,000 after acquiring an additional 27,592 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its position in shares of Alnylam Pharmaceuticals by 3.6% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 487,348 shares of the biopharmaceutical company’s stock valued at $134,035,000 after acquiring an additional 16,756 shares during the last quarter. Avoro Capital Advisors LLC boosted its stake in shares of Alnylam Pharmaceuticals by 33.3% during the 2nd quarter. Avoro Capital Advisors LLC now owns 400,000 shares of the biopharmaceutical company’s stock worth $97,200,000 after acquiring an additional 100,000 shares in the last quarter. Swiss National Bank grew its holdings in shares of Alnylam Pharmaceuticals by 0.3% in the 3rd quarter. Swiss National Bank now owns 375,400 shares of the biopharmaceutical company’s stock worth $103,246,000 after acquiring an additional 1,000 shares during the last quarter. Finally, Eagle Asset Management Inc. raised its position in shares of Alnylam Pharmaceuticals by 25.7% during the third quarter. Eagle Asset Management Inc. now owns 309,589 shares of the biopharmaceutical company’s stock worth $85,889,000 after purchasing an additional 63,385 shares during the period. Institutional investors own 92.97% of the company’s stock.

Insiders Place Their Bets

In other Alnylam Pharmaceuticals news, CEO Yvonne Greenstreet sold 5,219 shares of the business’s stock in a transaction on Tuesday, November 26th. The shares were sold at an average price of $250.98, for a total transaction of $1,309,864.62. Following the completion of the transaction, the chief executive officer now owns 78,880 shares of the company’s stock, valued at $19,797,302.40. The trade was a 6.21 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Tolga Tanguler sold 1,469 shares of the firm’s stock in a transaction dated Tuesday, November 26th. The shares were sold at an average price of $250.98, for a total value of $368,689.62. Following the completion of the sale, the executive vice president now directly owns 13,191 shares in the company, valued at approximately $3,310,677.18. This represents a 10.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 8,370 shares of company stock valued at $2,100,703 over the last 90 days. 1.50% of the stock is currently owned by company insiders.

Alnylam Pharmaceuticals Trading Down 0.3 %

Shares of NASDAQ:ALNY opened at $253.07 on Friday. The company has a current ratio of 2.75, a quick ratio of 2.69 and a debt-to-equity ratio of 31.64. The stock has a market capitalization of $32.64 billion, a PE ratio of -96.59 and a beta of 0.39. Alnylam Pharmaceuticals, Inc. has a 1 year low of $141.98 and a 1 year high of $304.39. The firm has a fifty day moving average price of $271.07 and a 200 day moving average price of $241.00.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings results on Thursday, October 31st. The biopharmaceutical company reported ($0.87) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.36). The firm had revenue of $500.90 million during the quarter, compared to the consensus estimate of $532.91 million. The business’s quarterly revenue was down 33.3% compared to the same quarter last year. During the same period in the previous year, the business posted $1.15 EPS. Analysts expect that Alnylam Pharmaceuticals, Inc. will post -2.21 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research firms recently weighed in on ALNY. Scotiabank increased their price target on Alnylam Pharmaceuticals from $305.00 to $310.00 and gave the company a “sector outperform” rating in a research report on Friday, November 1st. HC Wainwright reiterated a “buy” rating and issued a $400.00 target price on shares of Alnylam Pharmaceuticals in a report on Monday, November 18th. Royal Bank of Canada restated an “outperform” rating and set a $300.00 price target on shares of Alnylam Pharmaceuticals in a report on Friday, November 1st. Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $220.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Friday, October 11th. Finally, Bank of America boosted their target price on shares of Alnylam Pharmaceuticals from $307.00 to $314.00 and gave the company a “buy” rating in a research note on Monday, October 14th. One research analyst has rated the stock with a sell rating, six have issued a hold rating and eighteen have given a buy rating to the company’s stock. According to data from MarketBeat.com, Alnylam Pharmaceuticals has a consensus rating of “Moderate Buy” and an average target price of $298.09.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.